PNPLA3 and metabolic dysfunction-associated steatohepatitis: Furthermore, in mice carrying the human I148M mutant, ASO treatment improves inflammation and fibrosis.342 Based on these findings, AZD2693, a PNPLA3-targeting ASO, is currently being evaluated in a phase I trial in healthy overweight subjects and in patients with NASH who are PNPLA3-I148M homozygous.